Akebia Ther Financials
AKBA Stock | USD 2.06 0.01 0.49% |
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Current Ratio | 1.12 | 1.183 |
|
|
Investors should never underestimate Akebia Ther's ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Akebia Ther's cash flow, debt, and profitability to make informed and accurate decisions about investing in Akebia Ther.
Net Income |
|
Akebia | Select Account or Indicator |
Understanding current and past Akebia Ther Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Akebia Ther's financial statements are interrelated, with each one affecting the others. For example, an increase in Akebia Ther's assets may result in an increase in income on the income statement.
Please note, the presentation of Akebia Ther's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Akebia Ther's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Akebia Ther's management manipulating its earnings.
Akebia Ther Stock Summary
Akebia Ther competes with Protalix Biotherapeutics, Cidara Therapeutics, X4 Pharmaceuticals, Seres Therapeutics, and Ocean Biomedical. Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. Akebia Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 426 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
Instrument | USA Stock View All |
Exchange | NASDAQ Exchange |
ISIN | US00972D1054 |
CUSIP | 00972D105 |
Location | Massachusetts; U.S.A |
Business Address | 245 First Street, |
Sector | Biotechnology |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | www.akebia.com |
Phone | 617 871 2098 |
Currency | USD - US Dollar |
Akebia Ther Key Financial Ratios
Return On Equity | -5.53 | ||||
Profit Margin | (0.27) % | ||||
Operating Margin | (0.33) % | ||||
Price To Sales | 2.65 X | ||||
Revenue | 194.62 M |
Akebia Ther Key Balance Sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 771.2M | 644.1M | 525.6M | 351.8M | 241.7M | 411.2M | |
Other Current Liab | 124.1M | 125.3M | 104.2M | 71.0M | 61.2M | 67.9M | |
Net Debt | (39.1M) | (102.4M) | (13.8M) | 9.3M | 61.3M | 64.3M | |
Retained Earnings | (794.1M) | (1.2B) | (1.5B) | (1.6B) | (1.6B) | (1.5B) | |
Accounts Payable | 39.2M | 41.3M | 33.6M | 18.0M | 14.6M | 18.7M | |
Cash | 147.4M | 228.7M | 149.8M | 90.5M | 42.9M | 40.8M | |
Net Receivables | 38.9M | 26.9M | 51.6M | 41.1M | 39.3M | 28.3M | |
Other Current Assets | 6.6M | 14.9M | 33.1M | 32.9M | 20.2M | 12.6M | |
Total Liab | 376.4M | 396.5M | 449.1M | 342.5M | 272.3M | 247.7M | |
Total Current Assets | 309.5M | 371.4M | 272.0M | 184.9M | 118.1M | 112.2M | |
Other Assets | 76.0M | 64.9M | 640.3M | 94.5M | 108.7M | 112.1M | |
Short Term Debt | 5.0M | 5.3M | 102.3M | 36.7M | 24.0M | 20.8M | |
Other Liab | 65.0M | 88.4M | 158.9M | 158.2M | 182.0M | 95.8M | |
Net Tangible Assets | 48.5M | 48.4M | (86.7M) | (117.8M) | (106.0M) | (100.7M) | |
Capital Surpluse | 1.2B | 1.4B | 1.5B | 1.6B | 1.8B | 1.0B | |
Inventory | 116.3M | 61.0M | 38.2M | 21.8M | 15.7M | 14.9M | |
Intangible Assets | 291.2M | 144.2M | 108.1M | 72.1M | 36.0M | 34.2M | |
Net Invested Capital | 470.6M | 344.0M | 174.0M | 75.4M | 4.1M | 3.9M |
Akebia Ther Key Income Statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Interest Expense | 38.6M | 8.9M | 19.9M | 15.7M | 6.0M | 9.4M | |
Operating Income | (286.3M) | (376.4M) | (265.3M) | (63.2M) | (46.3M) | (48.6M) | |
Ebit | (286.3M) | (376.4M) | (265.3M) | (78.5M) | (44.5M) | (46.7M) | |
Research Development | 323.0M | 218.5M | 147.9M | 129.1M | 63.1M | 59.9M | |
Ebitda | (247.6M) | (342.9M) | (227.3M) | (43.3M) | (6.9M) | (7.2M) | |
Income Before Tax | (286.3M) | (383.5M) | (282.8M) | (92.6M) | (51.9M) | (54.5M) | |
Net Income | (279.7M) | (349.9M) | (244.9M) | (106.0M) | (51.9M) | (54.5M) | |
Income Tax Expense | (6.6M) | (33.6M) | (38.0M) | 13.4M | 41.7M | 43.8M | |
Total Revenue | 335.0M | 295.3M | 213.6M | 292.6M | 194.6M | 189.1M | |
Gross Profit | 189.7M | (601K) | 60.2M | 207.8M | 120.5M | 89.9M | |
Cost Of Revenue | 145.3M | 295.9M | 153.4M | 84.8M | 74.1M | 99.1M | |
Net Interest Income | 792K | (8.9M) | (19.9M) | (15.7M) | (6.3M) | (6.6M) |
Akebia Ther Key Cash Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Change In Cash | 42.7M | 81.3M | (79.3M) | (58.7M) | (48.6M) | (46.2M) | |
Free Cash Flow | (264.1M) | (110.7M) | (253.0M) | (73.3M) | (23.4M) | (24.6M) | |
Other Non Cash Items | 77.3M | 24.6M | 41.0M | (34.7M) | (1.9M) | (1.8M) | |
Capital Expenditures | 1.6M | 1.6M | 6.7M | 317K | 59K | 114K | |
Net Income | (279.7M) | (383.5M) | (282.8M) | (92.6M) | (51.9M) | (54.5M) | |
End Period Cash Flow | 149.8M | 231.1M | 151.8M | 93.2M | 44.6M | 42.4M | |
Depreciation | 38.6M | 33.6M | 38.0M | 37.7M | 41.8M | 43.9M | |
Change To Inventory | (29.1M) | 6.2M | (25.8M) | 19.8M | (2.5M) | (2.4M) | |
Investments | 32.1M | 217.8M | (39.7M) | 40M | (114K) | 0.0 | |
Change Receivables | (22.2M) | 12.0M | (24.0M) | 11.7M | 13.4M | 14.1M | |
Net Borrowings | (19K) | 62.7M | 20.0M | (33M) | (29.7M) | (28.2M) | |
Change To Netincome | 15.2M | 159.8M | 37.1M | 46.7M | 53.7M | 35.7M |
Akebia Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Akebia Ther's current stock value. Our valuation model uses many indicators to compare Akebia Ther value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Akebia Ther competition to find correlations between indicators driving Akebia Ther's intrinsic value. More Info.Akebia Ther is rated below average in return on equity category among its peers. It is number one stock in return on asset category among its peers . At present, Akebia Ther's Return On Equity is projected to drop slightly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Akebia Ther's earnings, one of the primary drivers of an investment's value.Akebia Ther Systematic Risk
Akebia Ther's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Akebia Ther volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Akebia Ther correlated with the market. If Beta is less than 0 Akebia Ther generally moves in the opposite direction as compared to the market. If Akebia Ther Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Akebia Ther is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Akebia Ther is generally in the same direction as the market. If Beta > 1 Akebia Ther moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Akebia Ther Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Akebia Ther's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Akebia Ther growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Akebia Ther November 28, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Akebia Ther help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Akebia Ther. We use our internally-developed statistical techniques to arrive at the intrinsic value of Akebia Ther based on widely used predictive technical indicators. In general, we focus on analyzing Akebia Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Akebia Ther's daily price indicators and compare them against related drivers.
Downside Deviation | 3.15 | |||
Information Ratio | 0.1044 | |||
Maximum Drawdown | 26.21 | |||
Value At Risk | (4.11) | |||
Potential Upside | 6.22 |
Complementary Tools for Akebia Stock analysis
When running Akebia Ther's price analysis, check to measure Akebia Ther's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Akebia Ther is operating at the current time. Most of Akebia Ther's value examination focuses on studying past and present price action to predict the probability of Akebia Ther's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Akebia Ther's price. Additionally, you may evaluate how the addition of Akebia Ther to your portfolios can decrease your overall portfolio volatility.
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |